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diagnosis is mandatory for all pancreatic mass, as its treatment and prognosis differs from adenocarcinoma. Radiotherapy may
be effective.
http://dx.doi.org/10.1016/j.rpor.2013.03.188
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Introduction. In localised gastric cancer, surgery remains the cornerstone of treatment. Nevertheless the dismal outcome has
led to a large debate regarding the role of adjuvant treatment in addition to surgery. The aim of the study was to evaluate the
outcome of adjuvant RCT in terms of local control and survival for locally advanced gastric cancer in our institution.
Materials. Between April-2001 and March-2012, 71 patients with locally advanced gastric cancer were treated with adjuvant
chemo-radiotherapy regimen. Median age was 66 (38–81) years. Location tumours were: cardias 9.9%, body-fundus 36.6% and
antro-pylorus 53.5%. 91.5% of patients received adjuvant bolus ﬂuoropyrimidine-based chemotherapy previous to concomitant
treatment; 7% receivedotherQTand1.4%none. 3DCRT radiotherapywasused, delivereddosewas 45–50.4Gy (1.8Gy/day) in 93%of
cases; 7%of cases didnot received treatment. Concomitant chemotherapy regimesusedwere 66.2% continuousﬂuoropyrimidine-
based chemotherapy, 29.6% bolus ﬂuoropyrimidine-based chemotherapy and 1.4% PFL; 2.8% of cases none. Pathologic stage was
11.3% IB, 23.9% IIA; 25.4% IIB, 18.3% IIIA, 21.1% IIIB. Surgery was performed in 100% of patients (total gastrectomy was 23.9%;
partial gastrectomy was 73.2% and 2.8% others).
Results. Median follow-up was 37, 5 months (7-98). 5-year actuarial overall survival (OS) was 60%; 5-year disease-free survival
(DFS) was 57%, and 5-year local progression free survival (LPFS) was 59%. Medium DFS was 61.53 months (95% CI: 51.7–71.35) and
medium OS was 66.07 months (95% CI: 56.73-75.42). Grade 3-4 toxicity: 7% diarrhea; 7% mucositis, 9.8% anemia; 1.4% neutropenia;
2.8% nauseas; 2.8% vomits; 2.8% asthenia, 2.8% anorexia and 1.4% hand-foot syndrome.
Conclusions. Prognosis of gastric cancer remains dismal, high relapse rates indicate the need for adjuvant therapy as an integral
part of treatment. Our results conﬁrm that adjuvant RCT is feasible approach for gastric cancer, offering good outcomes in-ﬁeld
tumour control, low toxicity proﬁle and overall survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.189
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Introduction. For themajority of patientswith stages II and III rectal cancer is recommended combined-modality therapy consisting
of radiation therapy, chemotherapy and surgery. Preoperative radiotherapy combined with oral capecitabine is considered as the
standard treatment in this situation.
Objective. The purpose of this study is to evaluate the results obtained with preoperative chemoradiotherapy using capecitabine
in terms of downstaging, distal and local recurrence and survival.
Method. Between January 2005 and December 2011, 117 patients with histological diagnosis of rectal adenocarcinoma stages II-III
were treated with preoperative 3D radiotherapy (50.4Gy) combined with capecitabine 825mg/m2/12h daily during the complete
course of radiation. Surgery was performed 6–8 weeks after the end of combined treatment. Staging workup in all patients
consisted in colonoscopy, endorectal ultrasound, pelvic MRI and PET-CT. Most of the patients were men and the mean age of
the series was 62 years. Clinical Staging TN was as follows: T2 (6%), T3 (71%), T4 (23%), N0 (38%), N1 (42%), N2 (20%). Surgical
procedures using total mesorectal excision were: low anterior resection (60%) and abdominoperineal resection (38%). The mean
follow-up of the series was four years.
Result. The rate of pathologic complete response obtained in this series was 22%. Tumor downstaging was observed in 66%, node
downstaging in 50.5% and TN downstaging in 34%. With a mean follow-up of more than four years the rate of local recurrence
observed was 5% and distance recurrence of 22%. The mean survival at four years was 88% and the disease free survival at four
years was 70%.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S211–S226 S213
Conclusion. Preoperative capecitabine combined with 3D radiotherapy is an adequate therapy in patients with rectal cancer in
stages II and III because provide considerable TN downstaging, pathologic complete response rate and good local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.190
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Objectives. To conﬁrm tolerance, pathological response (PR) rate and to evaluate local control (LC), disease free survival (DFS)
and overall survival (OS) rates in patients with locally advanced rectal cancer (LARC) treated with intensity-modulated radiation
therapy and concurrent capecitabine and oxaliplatin (IMRT-CAPOX), with long-term follow-up.
Patients and methods. Patients with diagnostic of T3–T4 and/or N0-N+ rectal cancer received Capecitabine 825mg/m2 b.i.d Mon-
day through Friday and oxaliplatin 60mg/m2 intravenously on days 1, 8, and 15, with IMRT (47.5Gy/20 fractions). Surgery was
scheduled 4–6 weeks after completion of CAPOX-IMRT. Toxicity was scored according to NCI-CTC and PR according to the grading
system proposed by MSKCC. LC, DFS and OS were calculated and Kaplan-Meier estimation evaluated signiﬁcant predictors of
survival.
Results. One hundred and forty patients were analyzed. No grade 4 toxicity was reported. Grade 1-2 rectitis was the most frequent
toxicity observed (74%). Grade 3 diarrhea and grade 3 rectitis was observed in 13 (9%) and 14 patients (10%), respectively. Median
time to surgerywas 6weeks. R0 resection ratewas 92%.One-hundred fourteenpatientswere pN0 (82%). Twenty patients (14%) had
a Grade 4 response (100% histologic response) and 49 patients (35%) grade 3+ (96–99% histologic response). With a median follow-
up of 5.2 years the LC rate is 98%. The 8y-OS and 8y-DFS rate is 89% (95% CI: 96.3–105.2) and 78% (95% CI: 88–99.5) respectively.
Eight-year DFS rate was signiﬁcantly higher in patients with grade 3+/4 PR (86% versus 71%, p=0.025) and in patients with pN0
(83% versus 59%, p=0.01).
Conclusion. Preoperative CAPOX-IMRT is a well-tolerated treatment with a low rate of grade 3 gastrointestinal toxicity and produce
a major pathological response in about 50% of the patients. The long follow-up of this study conﬁrms an excellent LC, DFS and
OS rate.
http://dx.doi.org/10.1016/j.rpor.2013.03.191
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Clear cell sarcoma is a rare type of malignancy, with poor prognosis. That shows features of melanocytic differentiation and
most commonly affects tendons and aponeuroses of the distal extremities, (the foot and ankle (43%) and the knees, wrists and
hands.) Gastrointestinal CCS is very rare, is a high grade soft tissue sarcoma with a distinct molecular proﬁle and morphological
features resembling malignant melanoma. This diagnosis avoids an unnecessary search for a primary melanoma and the natural
history of this tumor is not yet clear. We report the thirst case of clear cell sarcoma of the stomach. We describe a 57-year-old
male presented with a history of melena. Over the previous seven days Laboratory ﬁndings revealed anemia. The endoscopic
examination and EUS: showed: submucosa ulcerative lesion, about 6 cm in length. Pathology report from gastric biopsy material
demonstrated: submucosa ulcerative lesion compatible with a gastrointestinal stromal tumor (GIST) 4. In addition, no evidence
of lymph node or distant metastasis on abdominal computed tomography (CT) and PET-TC. Surgical procedures include: Billroth I
subtotal gastrectomy, and D2 lymph node dissection. Histological examination of the specimen revealed a tumor with epithelioid
cell characteristics and eosinophilic or clear cytoplasm and focal translucent nucleus. immunohistochemistry was positive for
S100 andHMB45 but negative for cytokeratin (AE1/AE3) and epithelial membrane antigen. The patient was referred to radiation
oncology and underwent a treatment with 3DCRT, a total dosis of 50.4Gy and faction of 1.8Gy daily. After 21 months of follow-up
with Upper endoscopy: and PET-TC every to six months. The patient remains asymptomatic without any clinical or radiological
evidence of recurrence.
http://dx.doi.org/10.1016/j.rpor.2013.03.192
